ERBB2 and ductal breast carcinoma in situ: The administration of a class II HER2 peptide-pulsed Type I polarized DC1 vaccine was shown to induce a strong anti-HER2 CD4+ Th1 response, with a pathologic complete response rate (pCR) among HER2+ ductal carcinoma in situ (DCIS) patients69–71.